1655P - High mRNA Expression of LMO4, A BRCA1 Downregulator, Correlates with Better Prognosis in Erlotinib-Treated Non-Small-Cell Lung Cancer (NSCLC) Patients (P) with EGFR Mutations

Abstract

ABSTRACT Background High BRCA1 mRNA levels affected progression-free survival (PFS) to erlotinib in EGFR-mutant NSCLC p (Rosell et al. CCR 2011). LMO4 is a negative regulator of BRCA1 function, and CtIP can bind to BRCA1 and LMO4. We have assessed the expression of CtIP, LMO4 and BRCA1 and examined the impact of CtIP and LMO4 levels on outcome. Methods mRNA expression of BRCA1, LMO4 and CtIP was examined by RT-PCR in the original pretreatment tumor biopsies of 72 erlotinb-treated NSCLC p with sensitive EGFR mutations. Results p characteristics: median age, 68; 61.8% female; 98.2% Caucasian; 63.6% never-smokers; 81.8% ECOG PS Conclusions Low BRCA1 and high LMO4 levels were associated with longer PFS in erlotinib-treated advanced NSCLC p with EGFR mutations. We recommend baseline assessment of BRCA1 and LMO4 mRNA expression to predict outcome and provide alternative individualized treatment to patients when indicated. HR 95%CI P BRCA1 ≤4.92 1 ref. 4.92-10.7 5.32 1.45-19.52 0.03 >10.7 5.13 1.25-20.99 0.02 CtIP ≤1.21 1 ref. 1.21-2.1 0.69 0.24-2.02 0.50 >2.1 1.10 0.42-2.89 0.84 LMO4 ≤1.29 6.02 1.51-23.94 0.01 1.29-1.86 2.81 0.85-9.21 0.09 >1.86 1 ref. Disclosure All authors have declared no conflicts of interest.